X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
USA (Orange Book)
0
Europe
Canada
0
Australia
0
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
http://www.pharmafile.com/news/541395/type-2-diabetes-drug-rosiglitazone-increases-risk-heart-problems
https://www.bmj.com/company/newsroom/new-study-adds-to-evidence-of-diabetes-drug-link-to-heart-problems/
https://www.medpagetoday.com/blogs/revolutionandrevelation/76713
https://www.forbes.com/sites/johnlamattina/2018/11/06/no-matter-what-the-fda-decides-new-diabetes-drugs-will-still-require-cv-outcomes-trials/?ss=healthcare#36f072145098
https://www.forbes.com/sites/matthewherper/2018/10/24/fda-experts-may-reconsider-diabetes-drug-safety-rules/#2e4c1b2a76d7
https://www.dddmag.com/news/2018/01/novel-diabetes-drugs-sensitize-cancer-cells-chemotherapy-agents
https://www.forbes.com/sites/judystone/2017/03/11/rare-disease-patients-need-more-than-miracles-and-trumpcare/
http://www.fiercepharma.com/pharma-asia/az-taps-3sbio-for-help-driving-sales-two-diabetes-drugs-china
http://www.fiercepharma.com/pharma/scotus-silence-means-gsk-really-does-have-to-face-claims-its-avandia-marketing-violated-rico
https://www.statnews.com/pharmalot/2016/06/06/supreme-court-glaxo-racketeering-diabetes/
http://twofourinsight.com/teva-secures-final-fda-approval-market-exclusivity-some-versions-generic-avandaryl/
http://www.fiercepharma.com/story/nejm-study-finds-actos-holds-repeat-strokes-heart-attacks-insulin-resistant/2016-02-18
http://www.fiercepharma.com/story/lyxumias-cv-results-may-help-sanofis-case-approval-they-wont-score-it-point/2015-12-03
http://www.webmd.com/cancer/lymphoma/news/20150902/could-common-diabetes-drugs-help-fight-leukemia?src=RSS_PUBLIC
http://www.fiercepharma.com/story/sanofis-diabetes-franchise-one-step-closer-us-lyxumia-launch/2015-03-19
Market Place
Share 
